GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

fisetin   Click here for help

GtoPdb Ligand ID: 5182

PDB Ligand
Compound class: Natural product
Comment: Fisetin is a plant flavonoid. It is used as an ingredient in dietary supplements. It has been investigated for potential anti-inflammatory and senolytic-like actions [1]. It is a more potent senolytic than quercetin.

fisetin is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 1
Hydrogen bond donors 4
Rotatable bonds 1
Topological polar surface area 111.13
Molecular weight 286.05
XLogP 3.85
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES Oc1ccc2c(c1)oc(c(c2=O)O)c1ccc(c(c1)O)O
Isomeric SMILES Oc1ccc2c(c1)oc(c(c2=O)O)c1ccc(c(c1)O)O
InChI InChI=1S/C15H10O6/c16-8-2-3-9-12(6-8)21-15(14(20)13(9)19)7-1-4-10(17)11(18)5-7/h1-6,16-18,20H
InChI Key XHEFDIBZLJXQHF-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
Fisetin is a clinical candidate. In May 2024, ClinicalTrials.gov had ~15 registered active/recruiting fisetin studies. Click here to view the current list of ALL clinical trials involving fisetin.
COVID-19: Fisetin was investigated for potential therapeutic benefit to alleviate dysfunction and inflammation resulting from SARS-C0V-2 infection.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05416515 A Study of Fisetin to Treat Carpal Tunnel Syndrome Phase 2 Interventional Mayo Clinic
NCT06399809 Fisetin to Reduce Senescence and Mobility Impairment in PAD Phase 2 Interventional Northwestern University
NCT06133634 Fisetin to Improve Vascular Function in Older Adults Phase 1/Phase 2 Interventional University of Colorado, Boulder
NCT04476953 COVID-FISETIN: Pilot in SARS-CoV-2 of Fisetin to Alleviate Dysfunction and Inflammation Phase 2 Interventional Mayo Clinic
NCT05593588 Senolytics Treatment of Interstitial Lung Disease in Common Variable Immunodeficiency Phase 2 Interventional Mayo Clinic